| 2.51 0.11 (4.58%) | 09-12 10:15 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.18 |
1-year : | 3.72 |
| Resists | First : | 2.73 |
Second : | 3.18 |
| Pivot price | 2.45  |
|||
| Supports | First : | 2.37 |
Second : | 2.16 |
| MAs | MA(5) : | 2.4 |
MA(20) : | 2.45 |
| MA(100) : | 3.71 |
MA(250) : | 2.17 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 47.9 |
D(3) : | 38.6 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 6.23 | Low : | 0.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MBRX ] has closed below upper band by 29.1%. Bollinger Bands are 78.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.51 - 2.52 | 2.52 - 2.53 |
| Low: | 2.34 - 2.35 | 2.35 - 2.37 |
| Close: | 2.38 - 2.4 | 2.4 - 2.42 |
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Tue, 03 Sep 2024
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference – Company Announcement - Financial Times
Mon, 19 Aug 2024
Moleculin Biotech Raises Capital with Public Offering - TipRanks
Mon, 19 Aug 2024
Moleculin Announces Closing of up to $16.5 Million Public Offering - PR Newswire
Fri, 16 Aug 2024
Moleculin Biotech Secures Funding for Drug Development Programs - TipRanks
Wed, 14 Aug 2024
Moleculin Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Mon, 05 Aug 2024
Moleculin Biotech Advances to Phase 3 AML Trial - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 11 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | -11.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.7 % |
| Return on Equity (ttm) | -86.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -9.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.22 |
| PEG Ratio | 0 |
| Price to Book value | 0.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|